DEXOMETOMIDINE (50 MCG) FOR SAFE AND SEAMLESS EXTUBATION RESPONSE

Emergence from general anesthesia and tracheal extubation provoke profound sympathoadrenal activation, manifesting as tachycardia, hypertension, arrhythmogenesis, elevated intracranial/intraocular pressures, and airway hyperreactivity (Reel & Maani, 2023). This investigation evaluates the efficacy of a single pre-emptive 50 mcg intravenous dexmedetomidine bolus, administered 10 minutes pre-extubation, in attenuating this high-stress response (Gertler et al., 2001). A prospective, randomized, double-blind, controlled trial enrolled ASA PS I-III adults undergoing elective surgery with endotracheal intubation >60 minutes. Participants received either dexmedetomidine 50 mcg IV (n=10) or weren't administered anything (n=10). Primary endpoints included hemodynamic stability (heart rate, systolic/diastolic pressures), extubation quality (4-point Extubation Quality Scale), and cough suppression (Cough Severity Score). Secondary metrics encompassed respiratory parameters (SpO₂, respiratory rate, rapid shallow breathing index) and adverse events. Dexmedetomidine significantly blunted hemodynamic perturbations (p<0.05), reduced cough severity (median CSS 1 vs. 3, p<0.01), and optimized extubation quality (median EQS 1 vs. 3, p<0.01) (Wang et al., 2019). Transient bradycardia occurred in 20% of dexmedetomidine recipients without hemodynamic compromise. The intervention conferred cooperative sedation, negligible respiratory depression, and reduced postextubation analgesic requirements. Pre-extubation dexmedetomidine bolus is a potent pharmacologic strategy for mitigating sympathetic hyperactivation, enhancing hemodynamic and airway stability during emergence.